Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05208047
PHASE3

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Sponsor: Cogent Biosciences, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Additionally, a drug-drug interactions substudy will investigate the potential for CGT9486 to be a CYP3A4 inducer in approximately 16 patients who have received at least one prior line of therapy for GIST.

Official title: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

442

Start Date

2022-04-14

Completion Date

2026-09

Last Updated

2026-02-04

Healthy Volunteers

No

Interventions

DRUG

CGT9486 plus sunitinib

Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.

DRUG

CGT9486

Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.

DRUG

Sunitinib

Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.

DRUG

Sunitinib

Participants will receive sunitinib orally until study stopping rules are met.

DRUG

Midazolam

Participants will receive a single-dose of midazolam on Day 1 and Day 16

DRUG

CGT9486 plus sunitinib

Patients will receive CGT9486 orally starting on Day 2 and sunitinib starting on Day 16 until study stopping rules are met.

Locations (110)

Mayo Clinic

Scottsdale, Arizona, United States

University of Arizona- Cancer Center

Tucson, Arizona, United States

City of Hope

Duarte, California, United States

University of California, Los Angeles (UCLA)

Los Angeles, California, United States

University of California, San Diego (UCSD)

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Colorado Denver

Denver, Colorado, United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

University of Miami - Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Orlando Health Cancer Institute

Orlando, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Northwestern University

Chicago, Illinois, United States

University of Iowa Hospital and Clinics

Iowa City, Iowa, United States

University of Kansas Cancer Center

Kansas City, Kansas, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University

St Louis, Missouri, United States

Nebraska Methodist Hospital

Omaha, Nebraska, United States

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Duke University

Durham, North Carolina, United States

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Oregon Health & Science University (OHSU)

Portland, Oregon, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center - Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

University of Wisconsin - Carbone Cancer Center

Madison, Wisconsin, United States

Instituto Alexander Fleming

Buenos Aires, Argentina

Instituto Oncologico de Cordoba (IONC)

Córdoba, Argentina

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

Bankstown-Lidcombe Hospital

Bankstown, Australia

Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)

Campinas, Brazil

lnstituto Nacional de Cancer - INCA

Rio de Janeiro, Brazil

CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

São Paulo, Brazil

Alberta Health Services Cross Cancer Institute

Edmonton, Alberta, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Tom Baker Cancer Center

Calgary, Canada

Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)

Montreal, Canada

Instituto Oncologico FALP

Santiago, Chile

Centro de Oncologia de Precision, Universidad Mayor

Santiago, Chile

Masarykuv onkologicky ustav

Brno, Czechia

Fakultni nemocnice Olomouc - Oncology clinic

Olomouc, Czechia

Aarhus University Hospital

Aarhus, Denmark

Institut Bergonie

Bordeaux, France

Centre Oscar Lambret

Lille, France

Centre Leon Berard

Lyon, France

AP-HM - Hôpital de la Timone

Marseille, France

Centre Eugene Marquis

Rennes, France

ICO St-Herblain

Saint-Herblain, France

CHU de Toulouse - Hospital Rangueil

Toulouse, France

Gustave Roussy

Villejuif, France

Helios Klinikum Bad Saarow

Bad Saarow, Germany

Helios Klinikum Berlin-Buch

Berlin, Germany

Universitaetsklinikum Essen

Essen, Germany

Universitaetsklinikum Hamburg-Eppendorf

Hamburg, Germany

Medizinische Hochschule Hannover- Urology Oncology

Hanover, Germany

Universitaetsmedizin Mannheim

Mannheim, Germany

Hong Kong United Oncology Centre

Jordon, Hong Kong

Prince of Wales Hospital

Shatin, Hong Kong

Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika

Debrecen, Hungary

Centro Riferimento Oncologico - Aviano

Aviano, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

Bologna, Italy

ASST degli Spedali Civili di Brescia

Brescia, Italy

Azienda Ospedaliero-Universitaria Careggi

Florence, Italy

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

Meldola, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

Istituto Europeo di Oncologia

Milan, Italy

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Palermo, Italy

Policlinico Universitario Campus Bio-Medico

Roma, Italy

Istituto Clinico Humanitas

Rozzano, Italy

Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento

Verona, Italy

I Can Oncology Center SA De CV

Monterrey, Mexico

Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)

Amsterdam, Netherlands

UMC Groningen

Groningen, Netherlands

Stichting Radboud Universitair Medisch Centrum

Nijmegen, Netherlands

Erasmus MC

Rotterdam, Netherlands

Haukeland University Hospital - Bergen

Bergen, Norway

Oslo University Hospital

Oslo, Norway

Szpital Specjalistyczny w Brzozowie

Brzozów, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej

Gliwice, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow

Warsaw, Poland

Seoul National University Hosptial

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Korea University Guro Hospital

Seoul, South Korea

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Institut Catala d'Oncologia - L'Hospitalet

Barcelona, Spain

Hospital General Universitario Gregorio Maranon

Madrid, Spain

Hospital Clinico San Carlos

Madrid, Spain

Hospital Fundación Jiménez Díaz

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Clinico Universitario de Santiago de Compostela

Santiago de Compostela, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

Skane University Hospital Lund

Lund, Sweden

Karolinska University Hospital

Solna, Sweden

Chang Gung Memorial Hospital - Kaohsiung Branch

Kaohsiung City, Taiwan

National Taiwan University Hospital

New Taipei City, Taiwan

China Medical University Hospital

Taichung, Taiwan

Taipei Veterans General Hospital (VGHTP)

Taipei, Taiwan

Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)

Taoyuan District, Taiwan

Cambridge Addenbrooke's Hospital

Cambridge, United Kingdom

University College London Hospital

London, United Kingdom

Royal Marsden Hospital - Surrey

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, United Kingdom